|

AK117 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Akeso2

Indications

  • Cancer2
  • Locally Advanced Triple-negative Breast Cancer1
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
  • Metastatic Triple-Negative Breast Cancer1
  • Lung Cancer1

Other2 trials

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Phase 2
A Study of Ivonescimab in First-Line ES-SCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.